Each candidate counted once, at its most advanced phase, from the companies’ own pipeline pages; preclinical programmes excluded
Phase 1incl. Phase 1/2Phase 2incl. Phase 2/3Phase 3Approved
23 programmes in clinical trials, 5 approved · as listed 28 May 2026
Respiratory vaccines
mRNA-1365
mRNA-1345
mRNA-1018
SpikevaxmNEXSPIKEmRESVIAmCOMBRIAXmFLUSIVA
Latent & other vaccines
mRNA-1645mRNA-1469mRNA-1215
mRNA-1405mRNA-1647mRNA-1189mRNA-1195mRNA-1975mRNA-1982mRNA-1769
mRNA-1403
Oncology
mRNA-4106mRNA-4200mRNA-4194mRNA-2808mRNA-4203 + anzu-cel
mRNA-4359
Intismeran (mRNA-4157)×10
Oncology · mRNA immunotherapies
BNT1132/3BNT116×2Autogene cevumeran×2
Oncology · antibodies & immunomodulators
BNT314/GEN1059BNT317BNT32121/2BNT32131/2
Pumitamig (BNT327)×30Gotistobart (BNT316)×4
Oncology · antibody-drug conjugates
Sacituzumab drozuntecan (BNT325)1/2BNT32141/2BNT3291/2
BNT326/YL202×3
Trastuzumab pamirtecan (BNT323)×3Elfetabart drozuntecan (BNT324)×2
Infectious diseases
BNT1611/2BNT163BNT1641/2BNT1651/2BNT351
BNT166
Comirnaty